Valuation: Gilead Sciences, Inc.

Market Cap 167B 146B 135B 125B 237B 15,967B 241B 1,614B 634B 7,866B 629B 615B 27,041B P/E 2026 *
-47.8x
P/E 2027 * 17.5x
Enterprise Value 177B 155B 143B 132B 250B 16,869B 254B 1,705B 670B 8,310B 664B 650B 28,569B EV / Sales 2026 *
5.8x
EV / Sales 2027 * 5.17x
Free-Float
99.88%
Yield 2026 *
2.41%
Yield 2027 * 2.49%
1 day-3.26%
1 week+0.46%
Current month+3.06%
1 month+7.19%
3 months-6.32%
6 months+6.21%
Current year+6.09%
1 week 127.88
Extreme 127.88
137.7
1 month 121.79
Extreme 121.79
137.7
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
Jun. 30Sell

Chief Executive Officer

-15,000 0.0012%
Jun. 14Sell

Executive/Senior Manager

-3,000 0.0002%
Jun. 14Sell

Chief Financial Officer

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-3.24%+0.46%+13.68%+72.03% 167B
-2.67%-1.39%+49.68%+161.15% 1,085B
-0.95%-0.99%+62.83%+60.97% 624B
-1.41%-3.25%+26.41%+83.28% 442B
+0.33%-1.17%+27.98%+26.90% 332B
-3.89%-11.22%+20.78%+26.07% 277B
-0.02%-2.85%+25.27%+44.88% 282B
+0.66%-1.42%-29.26%-39.30% 217B
-0.37%-1.18%+20.56%+61.14% 196B
+0.14%+2.34%-5.84%-31.96% 138B
Average -1.22%-1.71%+21.21%+46.51% 376.01B
Weighted average by Cap. -1.55%-1.03%+33.54%+77.02%

Financials

2026 *2027 *
Net sales 30.47B 26.65B 24.58B 22.71B 43.08B 2,906B 43.81B 294B 115B 1,432B 114B 112B 4,922B 32.38B 28.32B 26.12B 24.13B 45.78B 3,088B 46.55B 312B 123B 1,521B 122B 119B 5,230B
Net income -3.37B -2.95B -2.72B -2.51B -4.77B -322B -4.85B -32.51B -12.77B -158B -12.66B -12.39B -545B 9.55B 8.35B 7.7B 7.12B 13.5B 911B 13.73B 92.04B 36.15B 449B 35.85B 35.07B 1,542B
Net Debt 9.46B 8.27B 7.63B 7.05B 13.38B 902B 13.6B 91.19B 35.81B 444B 35.52B 34.75B 1,528B -96.43M -84.35M -77.8M -71.86M -136M -9.2B -139M -930M -365M -4.53B -362M -354M -15.58B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-10 $129.96 -3.62% 3,275,942
26-07-09 $134.84 -0.72% 5,839,339
26-07-08 $135.82 -0.40% 8,454,142
26-07-07 $136.36 +5.21% 9,177,296
26-07-06 $129.61 -1.26% 10,729,369
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.84USD
Average target price
158.30USD
Spread / Average Target
+17.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock